Biosimilars and Biologics in Cancer Therapy: An Era in Therapeutic Strategies addresses challenges and opportunities in biosimilars and biologics, integrating the latest evidence, regulatory landscapes, economic implications, and strategies to enhance cancer management. The book aims to create an all-inclusive educational resource, bridge the gap between research and clinical practice, and inspire future research in oncology. It provides a comprehensive examination of cancer therapeutics, starting with an introduction to biologics and biosimilars, their historical development, and foundational principles. Sections explain mechanisms of action, drug development processes, regulatory landscapes, and clinical applications through case studies. Emerging therapeutic strategies, including combination therapies and personalized medicine, are also covered. This book benefits researchers, oncologists, pharmacologists, pathologists, and other healthcare professionals by offering up-to-date insights into the clinical aspects of biological medications and their biosimilars. Contributions from global experts ensure readers gain the latest advancements and practical guidance on integrating these therapies into clinical practice and research. - Provides an in-depth analysis of biologics and biosimilars, covering their historical development, mechanisms of action, drug development processes, and regulatory landscapes- Includes case studies and practical examples that highlight the use of biologics and biosimilars in cancer treatment, showcasing their efficacy, safety profiles, and emerging therapeutic strategies such as combination therapies and personalized medicine- Offers diverse and comprehensive perspectives, ensuring readers gain insights into the latest advancements and future directions in biosimilars and biologics, along with practical guidance for integrating these therapies into clinical practice and research

Biosimilars and Biologics in Cancer Therapy: An Era in Therapeutic Strategies addresses challenges and opportunities in biosimilars and biologics, integrating the latest evidence, regulatory landscapes, economic implications, and strategies to enhance cancer management. The book aims to create an all-inclusive educational resource, bridge the gap between research and clinical practice, and inspire future research in oncology. It provides a comprehensive examination of cancer therapeutics, starting with an introduction to biologics and biosimilars, their historical development, and foundational principles. Sections explain mechanisms of action, drug development processes, regulatory landscapes, and clinical applications through case studies. Emerging therapeutic strategies, including combination therapies and personalized medicine, are also covered. This book benefits researchers, oncologists, pharmacologists, pathologists, and other healthcare professionals by offering up-to-date insights into the clinical aspects of biological medications and their biosimilars. Contributions from global experts ensure readers gain the latest advancements and practical guidance on integrating these therapies into clinical practice and research. - Provides an in-depth analysis of biologics and biosimilars, covering their historical development, mechanisms of action, drug development processes, and regulatory landscapes- Includes case studies and practical examples that highlight the use of biologics and biosimilars in cancer treatment, showcasing their efficacy, safety profiles, and emerging therapeutic strategies such as combination therapies and personalized medicine- Offers diverse and comprehensive perspectives, ensuring readers gain insights into the latest advancements and future directions in biosimilars and biologics, along with practical guidance for integrating these therapies into clinical practice and research